Overview
Duodenal ulcers, often caused by the bacterium Helicobacter pylori (H. pylori), are mucosal defects in the duodenal lining that can lead to significant morbidity and pain. These ulcers are characterized by chronic inflammation and potential complications such as bleeding, perforation, and obstruction. They predominantly affect adults, with a higher prevalence in certain demographic groups including those with chronic gastritis, a history of smoking, and individuals with compromised immune systems. Early and accurate diagnosis and management are crucial in day-to-day practice to prevent complications and improve quality of life 12.Pathophysiology
The pathophysiology of duodenal ulcers caused by Helicobacter pylori involves a complex interplay of bacterial virulence factors and host immune responses. H. pylori adheres to the duodenal mucosa using adhesins like BabA, which facilitates colonization and persistence 2. The bacterium triggers a robust inflammatory response characterized by the recruitment of neutrophils and the release of pro-inflammatory cytokines such as TNF-α and IL-8. This chronic inflammation leads to increased gastric acid secretion and impaired mucosal defense mechanisms, including reduced prostaglandin synthesis and mucus production 2. Over time, these factors contribute to mucosal damage, erosion, and the formation of ulcers. Additionally, the peptidoglycan (PGN) components of H. pylori may modulate the immune response, potentially influencing both inflammatory and anti-inflammatory pathways within the duodenal environment 2.Epidemiology
The incidence and prevalence of duodenal ulcers vary globally but are notably influenced by factors such as geographic location, socioeconomic status, and healthcare access. In developed countries, the prevalence has decreased due to improved diagnostic techniques and widespread use of eradication therapies for H. pylori. However, in less developed regions, the prevalence remains higher, often exceeding 10% in certain populations 2. Age and sex distribution show a slight male predominance, with peak incidence typically occurring between the ages of 25 and 60 years. Risk factors include chronic gastritis, smoking, alcohol consumption, and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Trends over time indicate a decline in duodenal ulcer incidence following the advent of H. pylori eradication protocols, though sporadic cases persist due to incomplete treatment or reinfection 2.Clinical Presentation
Patients with duodenal ulcers often present with classic symptoms such as epigastric pain, typically occurring between meals or at night, and relieved by food intake or antacids. The pain can be described as burning or aching and may be exacerbated by stress or NSAID use. Atypical presentations might include vague abdominal discomfort, nausea, vomiting, or unexplained weight loss. Red-flag symptoms that necessitate urgent evaluation include severe, persistent pain, hematemesis (vomiting blood), melena (black, tarry stools), and signs of gastrointestinal bleeding such as dizziness or syncope. These symptoms warrant immediate referral for endoscopic evaluation and potential intervention 2.Diagnosis
The diagnostic approach for duodenal ulcers involves a combination of clinical assessment, laboratory tests, and endoscopic evaluation. Key steps include:Clinical History and Physical Examination: Detailed history focusing on symptomatology, risk factors (e.g., NSAID use, smoking), and family history of gastrointestinal disorders.
Laboratory Tests:
- Serology: Anti-H. pylori IgG antibodies can indicate past or current infection 2.
- Urea Breath Test: Positive result confirms active H. pylori infection 2.
- Stool Antigen Test: Detects H. pylori antigens in stool samples 2.
Endoscopy: Essential for visualizing the ulcer and obtaining biopsies for histopathological examination and rapid urease testing.
- Rapid Urease Test (CLO Test): Positive if H. pylori is present, with a sensitivity and specificity close to 100% 2.
- Histology: Biopsy samples analyzed for H. pylori organisms and signs of chronic inflammation 2.Differential Diagnosis:
Gastroesophageal Reflux Disease (GERD): Typically presents with heartburn and regurgitation, often relieved by antacids.
Peptic Ulcer Disease (PUD) in Other Locations: Gastric ulcers may present similarly but with different endoscopic findings.
Malignancy: Particularly in older patients or those with significant weight loss, endoscopic biopsy is crucial to rule out malignancy.
NSAID-Induced Ulcer: History of NSAID use is a key distinguishing factor, often without H. pylori infection 2.Management
First-Line Treatment
Triple Therapy: A combination of a proton pump inhibitor (PPI) such as omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7-14 days 2.
- Contraindications: Known resistance to clarithromycin or amoxicillin, severe renal impairment.
Quadruple Therapy: For clarithromycin-resistant strains: PPI, bismuth subsalicylate, metronidazole, and tetracycline for 10-14 days 2.Second-Line Treatment
Sequential Therapy: PPI + amoxicillin for 5 days, followed by PPI + clarithromycin + tinidazole for 5 days 2.
Concomitant Therapy: PPI + metronidazole + tetracycline + bismuth for 10-14 days 2.Refractory or Specialist Escalation
Evaluation for Resistance: Perform susceptibility testing if initial therapy fails.
Consultation with Gastroenterology: For complex cases, specialist evaluation may be necessary to tailor therapy based on resistance patterns and patient-specific factors.
Alternative Antibiotics: Consider fluoroquinolones or rifabutin in regions with high resistance rates 2.Complications
Common complications of duodenal ulcers include:
Gastrointestinal Bleeding: Requires urgent endoscopic intervention or blood transfusion.
Perforation: Presents with acute, severe abdominal pain and requires surgical intervention.
Peptic Stricture: May necessitate endoscopic dilation or surgical repair.
Gastric Outlet Obstruction: Often managed endoscopically but may require surgical bypass in severe cases.
Referral to a gastroenterologist is warranted for managing these complications, especially in cases of recurrent bleeding or perforation 2.Prognosis & Follow-Up
The prognosis for duodenal ulcers is generally good with appropriate treatment, particularly when H. pylori infection is eradicated. Successful eradication reduces the risk of recurrence significantly. Prognostic indicators include complete resolution of symptoms, absence of complications, and sustained negative H. pylori tests post-treatment. Recommended follow-up intervals typically include:
Initial Follow-Up: 4-6 weeks post-treatment to assess symptom resolution and confirm eradication status via urea breath test or stool antigen test.
Long-Term Monitoring: Annual reassessment in high-risk patients or those with recurrent ulcers to ensure sustained remission and rule out reinfection 2.Special Populations
Pregnancy: PPIs are generally considered safe in pregnancy, but use should be minimized. Alternative therapies like sucralfate may be considered for symptomatic relief 2.
Elderly: Increased risk of complications; careful monitoring and tailored dosing of medications are essential.
Comorbidities: Patients with liver disease may require dose adjustments of PPIs due to altered metabolism. Close monitoring of renal function is also crucial in managing NSAID-induced ulcers 2.Key Recommendations
Diagnose H. pylori Infection: Use a combination of urea breath test, stool antigen test, and rapid urease test for definitive diagnosis (Evidence: Strong) 2.
Initiate Triple Therapy: For first-line treatment, prescribe omeprazole, clarithromycin, and amoxicillin for 14 days (Evidence: Strong) 2.
Consider Resistance Patterns: In regions with high resistance, adopt quadruple therapy or sequential therapy (Evidence: Moderate) 2.
Monitor for Complications: Regularly assess patients for signs of bleeding, perforation, or obstruction, especially in high-risk groups (Evidence: Moderate) 2.
Ensure Eradication Confirmation: Perform follow-up testing 4-6 weeks post-treatment to confirm eradication (Evidence: Strong) 2.
Adjust Therapy for Resistance: Modify antibiotic regimens based on local resistance patterns (Evidence: Moderate) 2.
Manage NSAID Use: Advise caution with NSAID use and consider gastroprotective agents like PPIs in long-term users (Evidence: Moderate) 2.
Tailor Treatment in Special Populations: Adjust dosing and monitor closely in elderly patients and those with comorbidities (Evidence: Expert opinion) 2.
Promote Lifestyle Modifications: Encourage smoking cessation and moderation of alcohol intake (Evidence: Moderate) 2.
Regular Follow-Up: Schedule periodic reassessments to monitor for recurrence and manage long-term risks (Evidence: Moderate) 2.References
1 Mi H, Zhu A, Wang X, Chen J, Zhu D, Li X. Effect of steam heating on the quality and flavor of beef celery baozi filling. Journal of the science of food and agriculture 2026. link
2 Wu Z, Pan DD, Guo Y, Zeng X. Structure and anti-inflammatory capacity of peptidoglycan from Lactobacillus acidophilus in RAW-264.7 cells. Carbohydrate polymers 2013. link
3 Bauer SA, Schneider S, Behr J, Kulozik U, Foerst P. Combined influence of fermentation and drying conditions on survival and metabolic activity of starter and probiotic cultures after low-temperature vacuum drying. Journal of biotechnology 2012. link
4 Rusch A, Amend JP. Order-specific 16S rRNA-targeted oligonucleotide probes for (hyper)thermophilic archaea and bacteria. Extremophiles : life under extreme conditions 2004. link